10 Biotechnology Stocks to Buy Now

SGMO, CBST, CELG, ALKS, AMAG, SGEN, RIGL, PGNX, GRFS, PPHM improve in weekly rankings

   
10 Biotechnology Stocks to Buy Now

This week, ten Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

Sangamo BioSciences‘ (NASDAQ:SGMO) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). Sangamo BioSciences is engaged in the research, development and commercialization of novel transcription factors for gene regulation and gene modification. In Portfolio Grader’s specific subcategories of Earnings Revisions and Sales Growth, SGMO also gets A’s. For more information, get Portfolio Grader’s complete analysis of SGMO stock.

This week, Cubist Pharmaceuticals (NASDAQ:CBST) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Cubist Pharmaceuticals is involved in the research, development, and commercialization of pharmaceutical products in the acute-care market. The stock price has risen 8.3% over the past month, better than the 1% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of CBST stock.

Celgene (NASDAQ:CELG) earns an A this week, jumping up from last week’s grade of B. Celgene is a global integrated biopharmaceutical company engaged in the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. Wall Street has pushed the stock higher by 5.2% over the past month. For more information, get Portfolio Grader’s complete analysis of CELG stock.

Alkermes (NASDAQ:ALKS) improves from a C to a B rating this week. Alkermes is a fully integrated biotechnology company committed to developing medicines that will improve patients’ lives. For more information, get Portfolio Grader’s complete analysis of ALKS stock.

AMAG Pharmaceuticals‘ (NASDAQ:AMAG) gets a higher grade this week, advancing from a C last week to a B. AMAG Pharmaceuticals utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. For more information, get Portfolio Grader’s complete analysis of AMAG stock.

This is a strong week for Seattle Genetics (NASDAQ:SGEN). The company’s rating climbs to A from the previous week’s B. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. For more information, get Portfolio Grader’s complete analysis of SGEN stock.

Rigel Pharmaceuticals (NASDAQ:RIGL) shows solid improvement this week. The company’s rating rises from a C to a B. Rigel Pharma discovers and develops novel, small molecule drugs in four lead product development programs: allergy/asthma, autoimmune disorders, hepatitis C, and cancer. Wall Street seems to agree with the upgrade and has propelled the stock up 7.4% over the past month. For more information, get Portfolio Grader’s complete analysis of RIGL stock.

Progenics Pharmaceuticals‘s (NASDAQ:PGNX) ratings are looking better this week, moving up to an A from last week’s B. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The stock currently has a trailing PE Ratio of 8. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

This is a strong week for Grifols (NASDAQ:GRFS). The company’s rating climbs to A from the previous week’s B. Grifols S. A. develops, manufactures, and markets plasma derivatives, IV Therapy, Enteral nutrition, diagnostic systems, and medical materials. For more information, get Portfolio Grader’s complete analysis of GRFS stock.

The rating of Peregrine Pharmaceuticals (NASDAQ:PPHM) moves up this week, rising from a C to a B. Peregrine Pharmaceuticals is a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 151% over the past month. For more information, get Portfolio Grader’s complete analysis of PPHM stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2012/08/10-biotechnology-stocks-to-buy-now-sgmo-cbst-celg/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.